Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication
- PMID: 28368375
- DOI: 10.1038/bmt.2017.29
Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication
Abstract
The proportion of multiple myeloma patients in long-term complete response (LTCR-MM) for more than 6 years after autologous stem cell transplantation (ASCT) is small. To evaluate whether this LTCR is associated with a particular immune signature, peripheral blood samples from 13 LTCR-MM after ASCT and healthy blood donors (HBD) were analysed. Subpopulations of T-cells (naïve, effector, central memory and regulatory), B-cells (naïve, marginal zone-like, class-switched memory, transitional and plasmablasts) and NK-cells expressing inhibitory and activating receptors were quantified by multiparametric flow cytometry (MFC). Heavy/light chains (HLC) were quantified by nephelometry. The percentage of CD4+ T-cells was lower in patients, whereas an increment in the percentage of CD4+ and CD8+ effector memory T-cells was associated with the LTCR. Regulatory T-cells and NK-cells were similar in both groups but a particular redistribution of inhibitory and activating receptors in NK-cells were found in patients. Regarding B-cells, an increase in naïve cells and a corresponding reduction in marginal zone-like and class-switched memory B-cells was observed. The HLC values were normal. Our results suggest that LTCR-MM patients express a particular immune signature, which probably reflects a 'high quality' immune reconstitution that could exert a competent anti-tumor immunological surveillance along with a recovery of the humoral immunity.
Similar articles
-
CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation.Front Immunol. 2021 Sep 29;12:736137. doi: 10.3389/fimmu.2021.736137. eCollection 2021. Front Immunol. 2021. PMID: 34659226 Free PMC article.
-
T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.Biol Blood Marrow Transplant. 2020 Jan;26(1):7-15. doi: 10.1016/j.bbmt.2019.08.009. Epub 2019 Aug 21. Biol Blood Marrow Transplant. 2020. PMID: 31445183 Free PMC article.
-
Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2014 Apr;20(4):507-17. doi: 10.1016/j.bbmt.2014.01.001. Epub 2014 Jan 7. Biol Blood Marrow Transplant. 2014. PMID: 24406505
-
Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2019 May;19(5):e213-e220. doi: 10.1016/j.clml.2018.12.022. Epub 2019 Jan 3. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30878316 Free PMC article.
-
Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.Scand J Immunol. 2007 Oct;66(4):465-75. doi: 10.1111/j.1365-3083.2007.01993.x. Scand J Immunol. 2007. PMID: 17850592
Cited by
-
Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity.Cancers (Basel). 2021 Sep 28;13(19):4867. doi: 10.3390/cancers13194867. Cancers (Basel). 2021. PMID: 34638353 Free PMC article. Review.
-
Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.Transpl Immunol. 2022 Apr;71:101544. doi: 10.1016/j.trim.2022.101544. Epub 2022 Jan 31. Transpl Immunol. 2022. PMID: 35093506 Free PMC article.
-
Characterization and prognostic implication of delayed complete response in AL amyloidosis.Eur J Haematol. 2021 Mar;106(3):354-361. doi: 10.1111/ejh.13554. Epub 2020 Dec 4. Eur J Haematol. 2021. PMID: 33230879 Free PMC article.
-
Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment.Cancers (Basel). 2021 Mar 30;13(7):1589. doi: 10.3390/cancers13071589. Cancers (Basel). 2021. PMID: 33808201 Free PMC article. Review.
-
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy.Nat Commun. 2024 Nov 29;15(1):10396. doi: 10.1038/s41467-024-54543-0. Nat Commun. 2024. PMID: 39613747 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials